The importance of detecting breast cancer very early on cannot be emphasized enough. Thousands of lives have been saved thanks to early screening tests for this common yet highly fatal type of cancer, as catching any type of cancer before symptoms manifest increases the likelihood that the tumor is small and still confined to one part of the body.
Today, the National Cancer Institute's (NCI) recommendation is a mammogram every 1-2 years for women over 40 years old. This procedure is uncomfortable and involves radiation exposure. However, a promising new test may be a better option as it is non-invasive, requires only a blood sample, eliminates radiation exposure, and can be recommended to any patient.
BioTime, Inc.'s OncoCyte Corporation has partnered with Abcodia Ltd., a specialist in early screening tests, to develop a new non-invasive test for breast cancer that builds on OncoCyte's proprietary PanC-Dx™. This line of serum-based cancer diagnostics makes use of markers drawn from the company's thorough analysis of broad gene expression patterns found in several types of cancer. Today, OncoCyte is funding 4 clinical trials using PanC-Dx™